Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ICER
ICER
Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato
Fierce Pharma
Fri, 06/21/19 - 11:33 pm
Novartis
Mayzent
JNJ
Spravato
ICER
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
Endpoints
Thu, 05/23/19 - 10:08 am
Duchenne Muscular Dystrophy
ICER
Sarepta Therapeutics
Exondys 51
ICER seeks to make drug price research more accessible
Biopharma Dive
Mon, 05/20/19 - 11:10 pm
ICER
drug pricing
ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’
Endpoints
Fri, 05/10/19 - 10:20 am
JNJ
drug pricing
antidepressants
esketamine
Spravato
ICER
ICER's Growing Impact On Drug Pricing And Reimbursement
Forbes
Wed, 04/17/19 - 09:42 am
ICER
drug pricing
reimbursement
Should Biogen Investors Be Extra Nervous Right Now?
Motley Fool
Sun, 04/7/19 - 05:08 pm
Biogen
Alzheimer's disease
ICER
investors
Spinraza
Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER
Fierce Pharma
Thu, 04/4/19 - 11:54 am
Novartis
ICER
drug pricing
Zolgensma
gene therapy
spinal muscular atrophy
Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate
Xconomy
Wed, 03/13/19 - 10:21 am
Donald Trump
ICER
drug pricing
ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy
BioCentury
Sat, 02/23/19 - 04:36 pm
Novartis
Zolgensma
AVXS-101
spinal muscular atrophy
ICER
The list of shame no biopharma wants to join
EP Vantage
Mon, 02/4/19 - 11:42 am
ICER
drug pricing
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Fierce Pharma
Tue, 01/29/19 - 07:21 pm
Novartis
ICER
spinal muscular atrophy
alternative payments
drug pricing
gene therapy
Zolgensma
Cost watchdog ICER lays out plans to scrutinize pharma's costliest price hikes
Fierce Pharma
Mon, 01/21/19 - 10:51 am
ICER
drug pricing
ICER to probe for clinical justification of drug price hikes
BioCentury
Fri, 01/18/19 - 12:06 am
ICER
drug pricing
ICER says gene therapy may be more cost effective for spinal muscular atrophy
Yahoo/Reuters
Thu, 12/20/18 - 11:54 pm
Biogen
Spinraza
Novartis
spinal muscular atrophy
ICER
ICER weighing issuing advice on trial design
BioCentury
Mon, 10/15/18 - 11:52 pm
ICER
clinical trials
trial design
Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says
Biopharma Dive
Thu, 07/5/18 - 07:44 pm
insurers
ICER
migraines
CGRP
coverage limits
Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail
Fierce Pharma
Fri, 06/1/18 - 11:40 am
Amgen
ICER
Aimovig
migraines
AbbVie's elagolix could put pressure on budgets, ICER estimates
Biopharma Dive
Tue, 05/8/18 - 03:46 pm
AbbVie
endometriosis
ICER
Elagolix
Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing
Fierce Pharma
Tue, 04/17/18 - 11:33 am
Roche
Hemlibra
hemophilia
FDA
breakthrough status
ICER
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
BioWorld
Tue, 02/20/18 - 09:58 am
CAR-T
ICER
Gilead Sciences
Yescarta
Novartis
Kymriah
drug pricing
Pages
« first
‹ previous
1
2
3
4
next ›
last »